These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9635840)

  • 1. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
    Kennedy S; Duffy MJ; Duggan C; Barnes C; Rafferty R; Kramer MD
    Br J Cancer; 1998 May; 77(10):1638-41. PubMed ID: 9635840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
    Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
    Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
    Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
    Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.
    Nielsen BS; Rank F; Illemann M; Lund LR; Danø K
    Int J Cancer; 2007 May; 120(10):2086-95. PubMed ID: 17290405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.
    Del Vecchio S; Stoppelli MP; Carriero MV; Fonti R; Massa O; Li PY; Botti G; Cerra M; D'Aiuto G; Esposito G
    Cancer Res; 1993 Jul; 53(13):3198-206. PubMed ID: 7686450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
    Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
    Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
    Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
    Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
    Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
    Int J Cancer; 1994 Sep; 58(6):877-81. PubMed ID: 7927882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.
    Hildenbrand R; Glienke W; Magdolen V; Graeff H; Stutte HJ; Schmitt M
    Histochem Cell Biol; 1998 Jul; 110(1):27-32. PubMed ID: 9681686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane.
    Bastholm L; Nielsen MH; De Mey J; Danø K; Brünner N; Høyer-Hansen G; Rønne E; Elling F
    Biotech Histochem; 1994 Mar; 69(2):61-7. PubMed ID: 7515699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.